Skip to main
  1. Stocks
  2. Neumora Therapeutics Inc
  3. Forecast
NMRA

NMRA Stock Forecast & Price Target

NMRA Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Neumora Therapeutics is viewed favorably because its post-navacaprant strategy is increasingly centered on a more straightforward, catalyst-rich pipeline, with NMRA-898, NMRA-511, and NMRA-215 each offering differentiated mechanisms and meaningful upcoming updates. The company’s current cash and cash equivalents are expected to fund operations into 3Q27, while the 35% workforce reduction should deliver about $10 million in annualized savings, helping preserve capital through several key readouts. Despite the KOASTAL setback, the combination of a broad seven-program neuroscience pipeline, potential first- or best-in-class assets, and multiple data catalysts over the next 12–18 months supports a constructive long-term outlook.

Bears say

Neumora Therapeutics is facing a severe fundamental setback after discontinuing navacaprant development following KOASTAL-2/3, where it failed both the primary MADRS endpoint and the key SHAPS measure, undermining confidence in its KORA-based strategy. The results were essentially flat versus placebo across studies, with -12.2 vs -12.0 in KOASTAL-2 and -12.1 vs -12.1 after study optimizations in KOASTAL-3, suggesting the mechanism may not be central to treating anhedonia. The company is also cutting 35% of its workforce and expects only $10M in annualized savings, reinforcing the view that it must reset toward a smaller mid-stage biotech profile after losing a major program.

NMRA has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

NMRA Analyst Forecast & Price Prediction

Get the latest NMRA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NMRA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neumora Therapeutics Inc (NMRA) Forecast

Analysts have given NMRA a Buy based on their latest research and market trends.

According to 6 analysts, NMRA has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neumora Therapeutics Inc (NMRA)


NMRA Analyst Forecast & Price Prediction

Get the latest NMRA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NMRA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NMRA stock data and trends